Immunotherapy and Vaccination in Surgically Resectable Non-Small Cell Lung Cancer (NSCLC)
Early-stage NSCLC (stages I and II, and some IIIA diseases) accounts for approximately 30% of non-small cell lung cancer (NSCLC) cases, with surgery being its main treatment modality. The risk of disease recurrence and cancer-related death, however, remains high among NSCLC patients after complete s...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-06-01
|
| Series: | Vaccines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-393X/9/7/689 |
| _version_ | 1797529112267456512 |
|---|---|
| author | Li-Chung Chiu Shu-Min Lin Yu-Lun Lo Scott Chih-Hsi Kuo Cheng-Ta Yang Ping-Chih Hsu |
| author_facet | Li-Chung Chiu Shu-Min Lin Yu-Lun Lo Scott Chih-Hsi Kuo Cheng-Ta Yang Ping-Chih Hsu |
| author_sort | Li-Chung Chiu |
| collection | DOAJ |
| description | Early-stage NSCLC (stages I and II, and some IIIA diseases) accounts for approximately 30% of non-small cell lung cancer (NSCLC) cases, with surgery being its main treatment modality. The risk of disease recurrence and cancer-related death, however, remains high among NSCLC patients after complete surgical resection. In previous studies on the long-term follow-up of post-operative NSCLC, the results showed that the five-year survival rate was about 65% for stage IB and about 35% for stage IIIA diseases. Platinum-based chemotherapy with or without radiation therapy has been used as a neoadjuvant therapy or post-operative adjuvant therapy in NSCLC, but the improvement of survival is limited. Immune checkpoint inhibitors (ICIs) have effectively improved the 5-year survival of advanced NSCLC patients. Cancer vaccination has also been explored and used in the prevention of cancer or reducing disease recurrence in resected NSCLC. Here, we review studies that have focused on the use of immunotherapies (i.e., ICIs and vaccination) in surgically resectable NSCLC. We present the results of completed clinical trials that have used ICIs as neoadjuvant therapies in pre-operative NSCLC. Ongoing clinical trials investigating ICIs as neoadjuvant and adjuvant therapies are also summarized. |
| first_indexed | 2024-03-10T10:08:47Z |
| format | Article |
| id | doaj.art-ba6f2ca440c44b9b95b7e1533bc25f46 |
| institution | Directory Open Access Journal |
| issn | 2076-393X |
| language | English |
| last_indexed | 2024-03-10T10:08:47Z |
| publishDate | 2021-06-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Vaccines |
| spelling | doaj.art-ba6f2ca440c44b9b95b7e1533bc25f462023-11-22T01:22:59ZengMDPI AGVaccines2076-393X2021-06-019768910.3390/vaccines9070689Immunotherapy and Vaccination in Surgically Resectable Non-Small Cell Lung Cancer (NSCLC)Li-Chung Chiu0Shu-Min Lin1Yu-Lun Lo2Scott Chih-Hsi Kuo3Cheng-Ta Yang4Ping-Chih Hsu5Division of Thoracic Medicine, Department of Internal Medicine, College of Medicine, Chang Gung Memorial Hospital at Linkou, Taoyuan City 33305, TaiwanDivision of Thoracic Medicine, Department of Internal Medicine, College of Medicine, Chang Gung Memorial Hospital at Linkou, Taoyuan City 33305, TaiwanDivision of Thoracic Medicine, Department of Internal Medicine, College of Medicine, Chang Gung Memorial Hospital at Linkou, Taoyuan City 33305, TaiwanDivision of Thoracic Medicine, Department of Internal Medicine, College of Medicine, Chang Gung Memorial Hospital at Linkou, Taoyuan City 33305, TaiwanDivision of Thoracic Medicine, Department of Internal Medicine, College of Medicine, Chang Gung Memorial Hospital at Linkou, Taoyuan City 33305, TaiwanDivision of Thoracic Medicine, Department of Internal Medicine, College of Medicine, Chang Gung Memorial Hospital at Linkou, Taoyuan City 33305, TaiwanEarly-stage NSCLC (stages I and II, and some IIIA diseases) accounts for approximately 30% of non-small cell lung cancer (NSCLC) cases, with surgery being its main treatment modality. The risk of disease recurrence and cancer-related death, however, remains high among NSCLC patients after complete surgical resection. In previous studies on the long-term follow-up of post-operative NSCLC, the results showed that the five-year survival rate was about 65% for stage IB and about 35% for stage IIIA diseases. Platinum-based chemotherapy with or without radiation therapy has been used as a neoadjuvant therapy or post-operative adjuvant therapy in NSCLC, but the improvement of survival is limited. Immune checkpoint inhibitors (ICIs) have effectively improved the 5-year survival of advanced NSCLC patients. Cancer vaccination has also been explored and used in the prevention of cancer or reducing disease recurrence in resected NSCLC. Here, we review studies that have focused on the use of immunotherapies (i.e., ICIs and vaccination) in surgically resectable NSCLC. We present the results of completed clinical trials that have used ICIs as neoadjuvant therapies in pre-operative NSCLC. Ongoing clinical trials investigating ICIs as neoadjuvant and adjuvant therapies are also summarized.https://www.mdpi.com/2076-393X/9/7/689immunotherapyprogrammed death-ligand 1 (PD-L1)cytotoxic T-lymphocyte-associated protein 4 (CTLA-4)immune checkpoint inhibitornon-small cell lung cancer (NSCLC)cancer vaccination |
| spellingShingle | Li-Chung Chiu Shu-Min Lin Yu-Lun Lo Scott Chih-Hsi Kuo Cheng-Ta Yang Ping-Chih Hsu Immunotherapy and Vaccination in Surgically Resectable Non-Small Cell Lung Cancer (NSCLC) Vaccines immunotherapy programmed death-ligand 1 (PD-L1) cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) immune checkpoint inhibitor non-small cell lung cancer (NSCLC) cancer vaccination |
| title | Immunotherapy and Vaccination in Surgically Resectable Non-Small Cell Lung Cancer (NSCLC) |
| title_full | Immunotherapy and Vaccination in Surgically Resectable Non-Small Cell Lung Cancer (NSCLC) |
| title_fullStr | Immunotherapy and Vaccination in Surgically Resectable Non-Small Cell Lung Cancer (NSCLC) |
| title_full_unstemmed | Immunotherapy and Vaccination in Surgically Resectable Non-Small Cell Lung Cancer (NSCLC) |
| title_short | Immunotherapy and Vaccination in Surgically Resectable Non-Small Cell Lung Cancer (NSCLC) |
| title_sort | immunotherapy and vaccination in surgically resectable non small cell lung cancer nsclc |
| topic | immunotherapy programmed death-ligand 1 (PD-L1) cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) immune checkpoint inhibitor non-small cell lung cancer (NSCLC) cancer vaccination |
| url | https://www.mdpi.com/2076-393X/9/7/689 |
| work_keys_str_mv | AT lichungchiu immunotherapyandvaccinationinsurgicallyresectablenonsmallcelllungcancernsclc AT shuminlin immunotherapyandvaccinationinsurgicallyresectablenonsmallcelllungcancernsclc AT yulunlo immunotherapyandvaccinationinsurgicallyresectablenonsmallcelllungcancernsclc AT scottchihhsikuo immunotherapyandvaccinationinsurgicallyresectablenonsmallcelllungcancernsclc AT chengtayang immunotherapyandvaccinationinsurgicallyresectablenonsmallcelllungcancernsclc AT pingchihhsu immunotherapyandvaccinationinsurgicallyresectablenonsmallcelllungcancernsclc |